NATTOPHARMA: RE-ELECTION OF CHAIRMAN, AND ELECTION OF TWO NEW BOARD MEMBERS

Frode Marc Bohan was re-elected as Chairman of the Board of Directors for NattoPharma ASA at the company’s Annual General Meeting, held Friday 20th May, 2016. Frode Marc Bohan is re-elected for a period of two years, up until the ordinary Annual General Meeting in 2018.

The Annual General Meeting further resolved to increase the Board of Directors from 3 to 5 members. Stefan Halldén and Annette Emlqvist were elected for a two-year period, until the ordinary Annual General Meeting in 2018.

Stefan Halldén (50) is today working chairman of Life Science Sweden AB, a long time shareholder in NattoPharma and a valuable contributor to the development of the company. The last year he also held the position as a member of the Election Committee. Halldén has a long track record from international finance.

Anette Elmqvist (67) has an extensive operational experience from various health and pharma companies as Swedish Pharmacies, KabiVitrum AB, Pharmacia Biopharmaceuticals AB, Pharmacia & Upjohn AB, Active Biotech AB, PowderJect SBL Vaccin AB, SBL Vaccin AB and Unitech Biopharma AB. Today Elmqvist serve as VP Quality Assurance in Scandinavian Biopharma AB.

“The election of Stefan Halldén and Annette Elmqvist as members of the Board of Directors in NattoPharma ASA is continuing the efforts to move NattoPharma from an “entrepreneurial start-up company” within the dietary supplement business segment to a visible player within global biotechnology, nutraceutical and the pharmaceutical field. Annette Elmqvist extensive operational and pharmaceutical production experience will be a great asset for NattoPharma.  Combined with Stefan Halldén extensive financial background, I believe that the extended board will contribute greatly to the success of NattoPharma ASA” says Frode M. Bohan, Chairman of the Board in NattoPharma



For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, commercially available Vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com 

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.